Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia Clinical Trial

Official title:

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01614912
• Other study ID #: D1001057
• Secondary ID: JapicCTI-121860
• Status: Completed
• Phase: Phase 3
• Start date: August 2012
• Est. completion date: May 2015

Study information

• Verified date: April 2022
• Source: Sumitomo Pharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study evaluates the long term safety and efficacy of SM-13496 in patients with schizophrenia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 284
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• Patients who are considered by the investigator eligible for the present study with no significant safety concerns
• Patients who are fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provide written voluntarily consent to participate in the study

Exclusion Criteria:

• Patients who are planning pregnancy for the expected duration of the study
• Patients who are otherwise considered ineligible for the study by the investigator

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• SM-13496
40 or 80 mg once daily orally

Locations

Country	Name	City	State
Japan	69 Sites	Tokyo, Etc
Korea, Republic of	22 Sites	Seoul, Etc
Malaysia	10 Sites	Kuala Lumpur, Etc
Taiwan	14Sites	Taipei, Etc

Sponsors (1)

Lead Sponsor	Collaborator
Sumitomo Pharma Co., Ltd.

Countries where clinical trial is conducted

Japan,  Korea, Republic of,  Malaysia,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at LOCF Endpoint	The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.	DB baseline and up to 32 weeks (LOCF endpoint)
Secondary	Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at LOCF Endpoint	CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease.; Baseline in the prior study (D1001056, double-blind [DB] baseline) was defined as baseline of the prior study. Baseline in the present study (D1001057, extension [EXT] baseline) was defined as Week 6 in the prior study.; The last post-baseline visit data collected during the study treatment of the present study were carried forward and defined as the last observation carried forward (LOCF) endpoint.	DB baseline and up to 32 weeks (LOCF endpoint)
Secondary	Change From Baseline in PANSS Positive Subscale Score at LOCF Endpoint	The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.	DB baseline and up to 32 weeks (LOCF endpoint)
Secondary	Change From Baseline in PANSS Negative Subscale Score at LOCF Endpoint	The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.	DB baseline and up to 32 weeks (LOCF endpoint)
Secondary	Change From Baseline in PANSS General Psychopathology Subscale Score at LOCF Endpoint	The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.	DB baseline and up to 32 weeks (LOCF endpoint)
Secondary	Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs)	Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events are defined as adverse events with a start date on or after the date of initial administration of study drug in the present study through the end of follow-up or adverse events occurring before the date of initial administration of study drug in the present study and worsening during the study treatment in the present study.	EXT baseline and up to 26 weeks
Secondary	Proportion of Participants With TEAEs Leading to Discontinuation		EXT baseline and up to 26 weeks
Secondary	Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)	Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.	EXT baseline and up to 26 weeks